Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Pinna, Simone Mornese; Lupia, Tommaso; Scabini, Silvia; Vita, Davide; Benedetto, Ilaria De; Gaviraghi, Alberto; Colasanto, Irene; Varese, Alessandra; Cattel, Francesco; Rosa, Francesco Giuseppe De; Corcione, Silvia

doi:10.1016/j.intimp.2021.108200

Cited by 20 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typically, it is better if individuals are vaccinated prior to being infected, but the virus typically moves faster than the vaccination pace. In this regard, and given the impossibility of preventing infection, symptoms should be reduced to certain levels [ 94 ], and mAb’s is a pioneer in this aspect [ 93 , 95 ]. Despite the suitability of mAb’s as treatment, if its distribution effort is not as quick as the virus spread, many people’s health would worsen and severely influence patients’ quality of life, even the economy [ 96 ].…”

Section: Proposed Methodologymentioning

confidence: 99%

Systematic review of MCDM approach applied to the medical case studies of COVID-19: trends, bibliographic analysis, challenges, motivations, recommendations, and future directions

Alamoodi

Zaidan

Albahri

et al. 2023

Complex Intell. Syst.

View full text Add to dashboard Cite

When COVID-19 spread in China in December 2019, thousands of studies have focused on this pandemic. Each presents a unique perspective that reflects the pandemic’s main scientific disciplines. For example, social scientists are concerned with reducing the psychological impact on the human mental state especially during lockdown periods. Computer scientists focus on establishing fast and accurate computerized tools to assist in diagnosing, preventing, and recovering from the disease. Medical scientists and doctors, or the frontliners, are the main heroes who received, treated, and worked with the millions of cases at the expense of their own health. Some of them have continued to work even at the expense of their lives. All these studies enforce the multidisciplinary work where scientists from different academic disciplines (social, environmental, technological, etc.) join forces to produce research for beneficial outcomes during the crisis. One of the many branches is computer science along with its various technologies, including artificial intelligence, Internet of Things, big data, decision support systems (DSS), and many more. Among the most notable DSS utilization is those related to multicriterion decision making (MCDM), which is applied in various applications and across many contexts, including business, social, technological and medical. Owing to its importance in developing proper decision regimens and prevention strategies with precise judgment, it is deemed a noteworthy topic of extensive exploration, especially in the context of COVID-19-related medical applications. The present study is a comprehensive review of COVID-19-related medical case studies with MCDM using a systematic review protocol. PRISMA methodology is utilized to obtain a final set of (n = 35) articles from four major scientific databases (ScienceDirect, IEEE Xplore, Scopus, and Web of Science). The final set of articles is categorized into taxonomy comprising five groups: (1) diagnosis (n = 6), (2) safety (n = 11), (3) hospital (n = 8), (4) treatment (n = 4), and (5) review (n = 3). A bibliographic analysis is also presented on the basis of annual scientific production, country scientific production, co-occurrence, and co-authorship. A comprehensive discussion is also presented to discuss the main challenges, motivations, and recommendations in using MCDM research in COVID‐19-related medial case studies. Lastly, we identify critical research gaps with their corresponding solutions and detailed methodologies to serve as a guide for future directions. In conclusion, MCDM can be utilized in the medical field effectively to optimize the resources and make the best choices particularly during pandemics and natural disasters.

show abstract

Section: Proposed Methodologymentioning

confidence: 99%

Systematic review of MCDM approach applied to the medical case studies of COVID-19: trends, bibliographic analysis, challenges, motivations, recommendations, and future directions

Alamoodi

Zaidan

Albahri

et al. 2023

Complex Intell. Syst.

View full text Add to dashboard Cite

show abstract

“…There are no FDA-approve treatments for outpatients with newly diagnosed COVID-19. Monoclonal antibody therapy has demonstrated notable safety and efficacy for those at high-risk of hospitalization, but therapeutic options for low- and moderate-risk outpatients are lacking [ 36 ]. Moreover, the resources associated with antibody infusion limit its use in many locations.…”

Section: Immunomodulators For Outpatientsmentioning

confidence: 99%

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

McCarthy

2022

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction SARS-CoV-2, the virus that causes COVID-19, elicits a variety of host responses ranging from asymptomatic or mild illness in most people, to severe disease and critical illness in a subset of patients with systemic inflammation and hypoxemic respiratory failure. Areas Covered Heterogeneous clinical presentations are often driven by disparate responses of the host immune system, with severe disease associated with aberrant interferon signaling or cytokine storm syndrome. This manuscript examines current therapeutic approaches, including the use of immunomodulators such as corticosteroids, interleukin inhibitors, kinase inhibitors, fluvoxamine, and ivermectin, and also explores the ways that these therapies and others may be used to treat COVID-19 in the future. Expert opinion Modulation of the immune response has become a mainstay of treatment of COVID-19, although the optimal mechanism has not yet been defined and there is considerable controversy regarding clinical management. As time progresses, the therapeutic approach to COVID-19 will undoubtedly change, particularly as we learn more about the pathophysiology of SARS-CoV-2 infection.

show abstract

“…Monoclonal antibodies are being studied to evaluate their efficacy in treating and preventing COVID-19. To date, FDA authorized EUA for many investigational mAbs both for pre-exposure prophylaxis and managing post-exposure mild-to-moderate COVID-19 based on their clinical trial potency against a virus strain (Mornese Pinna et al, 2021). These include casirivimab and imedevimab, bamlanivimab and etesevimab, sotrovimab, tocilizumab, and bebtelovimab (Mornese Pinna et al, 2021).…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

“…Due to the increased frequency of omicron sub-variants BA.2, BA.4, and BA.5 in U.S. HHS regions, casirivimab and imedevimab, bamlanivimab and etesevimab, and sotrovimab are no longer authorized for post-exposure prevention of COVID-19 until further notice by the FDA. Tixagevimab together with cilgavimab is being used for pre-exposure prophylaxis and is found to be potent enough against new sub-variants (Mornese Pinna et al, 2021).…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Current Therapeutics Effective against SARS-CoV-2 Omicron Sub-Variants

Soma¹

2022

Scholars Bulletin

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 (COVID-19) is changing at a rapid pace due to accumulated mutations in the viral genetic code over time. As new variants of the virus continue to emerge and replace previous versions of the variants, therapeutics and vaccines are being constantly monitored and reviewed for their efficacy against the new strains. With the surge in new omicron sub-variants across the nation, U.S. Food and Drug Administration issued emergency use authorization to a new monoclonal antibody therapy called bebtelovimab replacing the previous sotrovimab that was effective against Omicron BA.1. The main objective of the paper is to review the current treatment options available to treat non-hospitalized mild-to-moderate COVID-19 caused by the new omicron sub-variants BA.2, BA.4, and BA.5. Scientists, pharmaceutical companies, and researchers have been proactive in conducting randomized, double-blinded, placebo-controlled clinical trials to test the safety and efficacy of therapeutics in managing COVID-19 in addition to testing the vaccine efficacy against new strains. The paper focuses on reviewing the results of these randomized controlled trials. The oral antiviral options paxlovid and molnupiravir, and intravenous (IV) bebtelovimab continue to show their efficacy against the new sub-variants BA.4 and BA.5. It is important for everyone to stay well-informed of the new treatment options and only opt for those medications that are currently authorized for use in treating mild-to-moderate COVID-19.

show abstract

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Cited by 20 publications

References 48 publications

Systematic review of MCDM approach applied to the medical case studies of COVID-19: trends, bibliographic analysis, challenges, motivations, recommendations, and future directions

Systematic review of MCDM approach applied to the medical case studies of COVID-19: trends, bibliographic analysis, challenges, motivations, recommendations, and future directions

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

Current Therapeutics Effective against SARS-CoV-2 Omicron Sub-Variants

Contact Info

Product

Resources

About